Tennessee Senate Approves Biomarker Testing Expansion for State Health Plans

TL;DR Tennessee’s Senate passed SB 0435, which would extend biomarker testing coverage to state employee health plans and TennCare. If Governor Bill Lee signs the bill, the state would become the 24th to adopt such a measure.

Context Biomarker testing measures genetic, protein, or other molecular markers to guide treatment decisions. The American Cancer Society says it helps doctors pick therapies that are more likely to work, sparing patients from ineffective drugs and unnecessary side effects. The society also notes growing use of biomarker data in Alzheimer’s, pre‑eclampsia, and arthritis research.

Key Facts The Senate voted to pass SB 0435, introduced by Sen. Shane Reeves (R‑District 14) and Rep. Brock Martin (R‑Huntingdon). The bill would add biomarker testing to the benefits of state employee health insurance and TennCare, the state’s Medicaid program. Cancer survivor Stephen Huff told WSMV that receiving biomarker testing was “life‑saving” and likely saved his life after his lung cancer diagnosis. If Governor Lee signs the legislation, Tennessee would join 23 other states that have already expanded coverage for biomarker testing.

What It Means Research, including multiple randomized controlled trials and meta‑analyses, shows biomarker‑guided therapy can improve treatment matching and outcomes. For patients, broader coverage means fewer delays in receiving tests that could steer them toward effective drugs and away from therapies unlikely to help. For the state, expanded access may reduce spending on ineffective treatments while potentially improving health outcomes for employees and low‑income residents. Practical takeaway: patients with cancer or other conditions should ask their providers whether biomarker testing is appropriate for their situation.

Watch next: whether Governor Lee signs SB 0435 and how state agencies implement the new coverage for employees and TennCare enrollees.